2022 Revenues ($USD) : $11,888,000,000
2022 R&D spend : $1,204,000,000
2022 Number of Employees : 41,000
Fiscal Year End : 12/31/2021
Company CEO : Michael Mahoney, president and CEO

Boston Scientific earlier this year spent $1.75 billion to boost its left heart access capabilities through the acquisition of Baylis Medical. The Baylis platforms offer advanced transseptal puncture, with uses in procedures including AFib ablation, left atrial appendage closure (LAAC) and mitral valve interventions. Boston Scientific didn’t stop shopping there. In June, it announced an agreement to purchase a majority stake in M.I. Tech, the Korea-based maker and distributor of medical devices for endoscopic and urologic procedures. M.I. Tech is the creator of the Hanarostent family of conformable, non-vascular, self-expanding metal stents. In other news, Boston Scientific announced positive outcomes from studies of its Acurate Neo2 aortic valve system. The Acurate Neo2 represents the company’s bid to compete again in the TAVR space, nearly two years after shutting down its Lotus program. –CN